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COMPOSITIONS COMPRISING HUMAN 
IMMUNODEFICIENCY VIRUS TAT 
ADSORBED TO THE SURFACE OF ANIONIC 
NANOPARTICLES 
RELATED APPLICATIONS 
This application is a US. National Phase under 35 U.S.C. 
371 of PCT.US03/05806 ?led Feb. 27, 2003, Which in turn 
claims the bene?t of US. Provisional application No. 60/ 361 , 
043, ?led on Mar. 1, 2002 the entire contents of each of Which 
are hereby incorporated by reference. 
FIELD OF THE INVENTION 
The present invention relates to therapeutic agents and 
methods for treating HIV infection. More speci?cally, the 
invention relates to compositions of matter that include an 
immunostimulatory recombinant transcriptional Tat protein 
of the HIV and a Tat-adsorbed nanoparticle that evoke 
T-helper (Th), cytotoxic T-lymphocyte (CTL), and antibody 
immune responses. 
BACKGROUND OF THE INVENTION 
The human immunode?ciency virus (HIV) is a member of 
the lentivirus family of animal retroviruses. Lentiviruses, 
including visna virus of sheep, and the bovine, feline and 
simian immunode?ciency viruses (SIV), are capable of long 
term latent infection in cells and short-term cytopathic 
effects, and they all produce sloWly progressive, fatal dis 
eases, Which include Wasting syndromes and central nervous 
system degeneration. TWo closely related types of HIV, des 
ignated HIV-1 and HIV-2, have been identi?ed. HIV-1 and 
HIV-2 differ in genomic structure and antigenicity, sharing 
only 40 percent nucleic acid sequence homology. Nonethe 
less, both forms of HIV cause similar clinical syndromes. 
HIV infection ultimately results in impaired function of 
both the speci?c and innate immune systems. The most 
prominent defects are in cell-mediated immunity and they 
can be attributed to a lack of CD4+ T cells, and/or abnormali 
ties in immune system function With normal CD4+ T cell 
counts. The hallmark of the progression of HIV-induced dis 
ease is the diminishing number of CD4+ T cells in the periph 
eral blood, from a normal of about 1000/mm3 to less than 
100/mm3 in fully developedAIDS. Since CD4+ helper T cells 
are essential for both cell-mediated and humoral immune 
responses to various microbes, the loss of these lymphocytes 
is a major reason Why AIDS patients become susceptible to so 
many infections. The loss of CD4+ cells may occur after 
several months or take longer than 10 years in different indi 
viduals. 
HIV gene expression may be divided into an early stage, 
during Which regulatory genes are expressed, and a late stage, 
during Which structural genes are expressed and full-length 
viral genomes are packaged. Expression of the early regula 
tory genes, including Tat, requires sequential RNA splicing 
events in the nucleus that generate short mRNAs, Which are 
then transported to the cytoplasm and are subsequently trans 
lated into proteins. The Tat gene encodes a protein that binds 
to a sequence present in the long terminal repeats (LTR) 
called the transactivating response element (TAR), resulting 
in enhanced viral gene expression. Binding of the Tat protein 
to the viral LTR causes a 1000-fold increase in RNA poly 
merase II-catalyZed transcription of the provirus, and is 
required for replication of the virus (Abbas, A. K. et al. 1997 
in Cellular and Molecular Immunology, ch 21, 450-459). 
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Tat is released from cells at relatively high levels and can be 
detected in the serum of HIV infected individuals. It is rapidly 
taken up by other cells through binding mediated by the basic 
domain of the molecule (Ma, M. and Nath, A. 1997 J. Virol. 
71:2495). This feature alloWs extracellular Tat to transacti 
vate latent HIV in other cells (Frankel, A. D. and Pabo C. O., 
1998 Cell 55: 1 189; Li, C. J. et al. 1997 Proc. Natl. Acad. Sci. 
USA 94:8116). It also alloWs for Tat to transactivate other 
cellular processes, causing altered intracellular signaling in a 
variety ofcell types (Li, C. J. et al. 1997 Proc. Natl. Acad. Sci. 
USA 94:8116;Viscidi, R. P. etal. 1989 Science 246: 1 606; Li, 
C. J. et al. 1995 Science 268:429; Westendorp, M. O. et al. 
1995 Nature 375:497; Kolesnitchenko, V. et al. 1997 J. Virol. 
71:9753). A consequence of these events is severe immuno 
suppressive. HoWever, most of these studies have been con 
ducted in vitro at nanomolar concentrations of Tat, and it is 
unclear to What extent this occurs in vivo. Extracellular Tat 
also causes rapid calcium ?uxes in neurons and other cell 
types (Nath, A. et al. 1996 J. Virol. 70:1475; Nath, A. et al. 
1996 J. Neurovirol. 2:17; Holden, C. P. et al. 1999 Neuro 
science 91:1369; Haughney, N. J. et al. 1998 J. Neurovirol. 
4:353; Nath, A. et al. 2000 Ann. Neurol. 47 (January 2000); 
Haughney, N. J. et al. 1999 J. Neurochem. 73:1363). 
Interestingly, this rapid internaliZation of Tat also results in 
the e?icient entry of Tat into the MHC class I processing 
pathWay (Moy, P. et al. 1996 Mol. Biotechnol. 6:105; FaWell, 
S. et al. 1994 Proc. Natl. Acad. Sci. USA 91 :664; Kim, D. T. 
et al. 1997 J. Immunol. 159:1666). In fact, a single peptide 
consisting of amino acids 49 to 57 of Tat Was shoWn to 
facilitate the transport of ovalbumin (OVA) into the class I 
pathWay (Moy, P. et al. 1996 Mol. Biotechnol. 6: 105). Thus, 
the internalization of Tat and entry into the class I pathWay 
Would be expected to enhance the development of cytotoxic 
T-lymphocyte (CTL) responses aimed at Tat epitopes, if its 
transactivating activity Were blocked. Inactivation of the 
transactivation responses aimed at Tat epitopes has been 
achieved by mutating residue Cys 22 to Gly. The mutated Tat 
functions as a dominant negative (Rossi, C. et al. 1997 Gene 
Ther. 4:1261; Caputo, A. et al. 1996 Gene. Ther. 3:235). 
Several studies have shoWn that Tat is immuno suppressive. 
Tat can induce apoptosis in T cells by a process that involves 
activation of cellular cyclin dependent kinases (Li, C. J. et al. 
1995 Science 268:429). Recently, Tat has been shoWn to 
up-regulate FasL on macrophages (Wu, M. X. and Schloss 
man, S. F. 1997 Pro. Natl. Acad. Sci. USA 94:13832; Dock 
rell, D. H. et al. 1998 J. Clin. Invest. 101:2394) and T cells 
(Westendorp, M. O. et al. 1995 Nature 375:497), resulting in 
apoptosis of the Fas expressing T cells. On the other hand, Tat 
has been shoWn to prevent apoptosis in some systems (Zauli, 
G. et al. 1993 Cancer Res. 53:4481). HoWever, most ofthese 
studies have been conducted in vitro, and it is unclear to What 
extent Tat is immunosuppressive in vivo. A recent study by 
Cohen et al. (Cohen, S. S. et al. 1999 Proc. Natl. Acad. Sci. 
USA 96:10842) has shoWn that immunization using Tat in 
complete Freund’s adjuvant (CFA) suppressed the response 
to a co-administered antigen, and that this effect Was abro 
gated by oxidation of the Tat molecule. It Would be desirable 
to evaluate the immunosuppressive properties of Tat in an in 
vivo system. 
Tat from the human immunode?ciency virus type 1 (HIV 
1) is an RNA binding transcriptional protein that is expressed 
early in HIV infection, and is necessary for high level expres 
sion of viral proteins (Garber, M. E. and Jones, K. A. 1999 
Curr. Opin. Immunol. 1 1:460). Tat comprises 86 to 102 amino 
acids that are encoded by 2 exons, and Tat protein comprise 
?ve functional domains (Bayer, P. et al. 1995 J. Mol. Biol. 
247:529). The ?rst 72 amino acids are encoded by exon 1 and 
US 7,588,764 B2 
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exhibit full transactivating activity. The amino terminal 
domain spans the ?rst 21 amino acids; the cysteine-rich 
domain spans amino acids 22-37 and represents the transac 
tivation domain; the basic domain spans amino acids 49-72, 
and contains the nuclear localization signal sequences, Which 
facilitate the binding of Tat to Tat-responsive elements as Well 
as the uptake of Tat by the cell (Jones, K. A. and Peterlin, B. 
M. 1994 Ann. Rev. Biochem. 631717; Chang H. C. et al. 1997 
Aids 1111421; Barillari, G. et al. 1993 Proc. Natl. Acad. Sci. 
USA 9017941). The second exon encodes the amino acid 
C-terminal sequence, Which varies among different strains of 
HIV-1 from amino acids 73 to 86 or 73 to 102. The C terminus 
is not required for transactivation but does contain an RGD 
(arginine-glycine-aspartate) motif, Which is important in 
binding to cell surface molecules and the extracellular matrix 
(Chang H. C. et al. 1997 AIDS 1111421). The inventors have 
shoWn that the second exon of Tat in?uences the tertiary 
con?guration of Tat and greatly potentiates Tat uptake (Ma, 
M. and Nath, A. 1997 J. Virol. 7112495). 
Tat is an unusual transcription factor as it can be released 
from cells and enter cells, While retaining its transactivating 
activity, Which enables it to up-regulate a number of genes. It 
appears that the basic domain of Tat is important, not only for 
translocation and for nuclear localiZation but also for trans 
activation of cellular genes. As such, targeting of Tat protein 
or, more simply, the basic protein provides great scope for 
therapeutic intervention in HIV-1 infection. 
Modern vaccines typically consist of either a killed (inac 
tivated) or a live, nonvirulent (attenuated) form of an infec 
tious agent. Traditionally, the infectious agent is groWn in 
culture, puri?ed, and either inactivated or attenuated Without 
losing the ability to evoke an immune response that is effec 
tive against the virulent form of the infectious organism. 
Notwithstanding the considerable success that has been 
achieved in creating effective vaccines against numerous dis 
eases, AIDS is one disease that is not preventable through the 
use of traditional vaccines. 
The task of developing an effective vaccine for immuno 
prophylaxis against HIV has been complicated by the genetic 
potential of the virus for great antigenic variability. This effort 
has largely been directed to proteins of the virus that are 
expressed on the surface of infected cells, Which are recog 
niZed by cytotoxic T cells. The T cell response eliminates 
infected cells, While free virus is blocked and cleared by 
antibodies to surface antigens of the viron. Limitations of this 
mode of vaccination are readily apparent in HIV- 1, Which has 
demonstrated a great diversity in immunogenic viral epitopes 
and rapid mutational variations that occur Within and betWeen 
infected individuals. 
On the other hand, intracellular Tat is ef?ciently processed 
by major histocompatibility complex (MHC) class 1 for pre 
sentation to cytotoxic T lymphocytes (CTL). CTL responses 
have been detected repeatedly in individuals infected With 
HIV (van Baalen, C. A. et al. 1997 J. Gen. Virol. 7811913; 
Venet, A. et al. 1992 J. Immunol. 14812899; Froebel, K. S. et 
al. 1994 AIDS Res. Hum. Retroviruses 101S83; Ogg, G. S. et 
al. 1998 Science 27912103), and other studies have shoWn 
that the presence of anti-Tat CTL during the initial phase of 
infection, correlates inversely With the progression of the 
infection to AIDS disease (Re, M. C et al. 1995 J. Aquir. 
Immune De?c. Syndr. Hum. Retrovirol. 101408). Tat also 
shoWs very little variation betWeen HIV subtypes, and the 
?rst exon is highly conserved among the different subtypes, 
except the 0 subtype (Gringeri, A. et al. 1998 J. Hum. Virol. 
11293). Because of these properties, Tat is an attractive can 
didate as a vaccine. Current studies on the development of a 
Tat vaccine utiliZe inactivated Tat “toxoid” in an effort to 
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prevent the toxic and immunosuppressive effects of Tat 
(Gringeri, A. et al. 1998 J. Hum. Virol. 11293; Gallo, R. C. 
1999 Proc. Nat. Acad. Sci. USA 9618324; Gringeri, A. et al. 
1999 J. Aquir. Immune De?c. Syndr. Hum. Retrovirol. 
201371). Tat toxoid has been administered in incomplete Fre 
und’s adjuvant to HIV seronegative people, and has been 
shoWn to safely induce modest antibody and DTH responses 
(Gringeri, A. et al. 1998 J. Hum. Virol. 11293; Gringeri,A. et 
al. 1999 J. Aquir. Immune De?c. Syndr. Hum. Retrovirol. 
201371). HoWever, the use of a denatured molecule may 
destroy important epitopes and prevent Tat from ef?ciently 
entering cells for an optimum immune response. Also, current 
immunization strategies Would not be expected to induce T 
helper 1 (Th1), or CTL responses, Which are critical for 
antiviral immune responses. Biologically active Tat has been 
used to immuniZe monkeys (Cafaro, A. et al. 1999 Nat. Med. 
51643). This vaccination protocol achieved partial protection 
against the highly pathogenic SHIV virus. HoWever, it is 
conceivable that had the immunosuppressive effect of Tat 
been abolished, a better immune response could have been 
attained. 
The present inventors have discovered that Tat produced by 
recombinant methods tightly binds bacterial RNA, Which 
conventional methods of puri?cation of recombinant Tat are 
unable to remove from the protein. This tightly bound RNA 
tends to mask antigenic sites (epitopes) on the Tat protein. 
Stimulation of the immune system by recombinant Tat pro 
tein is thereby attenuated, Which in turn reduces the Tat pro 
tein’s usefulness as a vaccine. 
The present inventors have also discovered that highly 
puri?ed Tat does not cause immuno-suppression When given 
as a vaccine in mice, While still inducing a strong immune 
response. Moreover, recombinant Tat has heretofore been 
puri?ed by reverse-phase HPLC, Which gives rise to denatur 
ation of the protein and concomitant loss of important 
epitopes. Thus, the conventional puri?cation methodology 
results in less-than-optimal immunogenic recombinant Tat 
protein. 
Heretofore, Tat has been produced by synthetic proce 
dures. While the primary structure (amino acid sequence) of 
Tat can be attained by such methodology, the harsh chemical 
conditions required for such synthesis tend to interfere With 
protein folding. Thus, it has not been heretofore possible to 
faithfully produce a Tat protein by synthetic methods that 
possess naturally occurring Tat protein’ s tertiary structure. As 
a result, purely synthetic methods tend to produce Tat protein 
that lacks some or all of the epitopes that are present in 
naturally-occurring Tat protein, again resulting in less-than 
optimal immune stimulation by recombinant Tat protein. 
There is thus a need for a method for producing a recom 
binant Tat protein that possesses a tertiary structure that has 
not been compromised by harsh synthetic chemicals. 
There is also a need for a method for producing recombi 
nant Tat protein that is free of masking of antigenic sites by 
bacterial RNA. 
There is also a need for a recombinant Tat protein that 
possesses the ability to be internaliZed by cells and that is not 
immunosuppressive. 
There is also a need for a recombinant Tat protein that is 
processed via the MHC class I pathWay. 
There is also a need for an effective immunogen and a 
method for effectively eliminating Tat-expressing cells by 
evoking strong Th1 and CTL responses, and resulting in an 
effective vaccine against HIV. 
Furthermore, protein-based vaccines, such as recombinant 
Tat, are often more effective if administered With at least one 
adjuvant to enhance their potency (T. W. Baba, V. Liska, A. H. 
US 7,588,764 B2 
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khimani, N. B. Ray, P. J. Dailey, D. Penninck et al., Nat. Med. 
1999 5 194-203). Unfortunately, after decades of research, 
insoluble aluminum salts. (generally called as “Alum”) still 
represent the only approved adjuvants for human use in the 
US (R. K. Gupta, G. R. Siber, 1995 13 1263-1276).Alum has 
been used as vaccine adjuvant for many years. However, it is 
not a potent adjuvant for recombinant proteins, and more 
importantly, it does not help in cell-mediated immune 
responses (R. K. Gupta, E. H. Relyveld, E. B. Lindblad, B. 
BiZZini, S. Ben-Efraim, C. K. Gupta, Vaccine. 1993 11 293 
306). It is Well knoWn that, With protein-based vaccines, Alum 
as adjuvant only helps humoral immune responses, charac 
teriZed by enhanced antibody production and the type-2 CD4 
T helper cell (Th2) responses, such as enhanced release of 
cytokines like interleukin 4 (IL-4) and/or the enhanced pro 
duction of IgG subtype IgG1 (R. K. Gupta, G. R. Rost, E. 
Relyveld, G. R. Siber, Adjuvant properties of aluminum and 
calcium compounds, In: M. F. PoWell, M. J. NeWman (Eds.), 
Vaccine design: the subunit and adjuvant approach, Plenum 
Press, NeW York, 1995, p 229-248). Therefore, there exists a 
clear need to develop alternative and improved vaccine adju 
vants and/ or delivery systems, especially those that can help 
in cell-mediated immune responses, for protein-based vac 
cines, such as recombinant Tat protein. 
Over the last several decades, many other potential vaccine 
adjuvants have been developed (M. Singh, D. T. O’Hagan, 
Nat. Biotech. 1999 17 1075-1081). Some of them Were 
proven to help in cell-mediated immune responses. LipidA is 
one example. The adjuvant effect of the lipopolysaccharide 
(LPS) from Salmonella Minnesota R595 (Re) Was ?rst 
described as early as in 1956 (J. T. Ulrich, K. R. Myers. 
Monophosphoryl lipidA as an adjuvant: past experiences and 
neW directions. In: Vaccine design: The subunit and adjuvant 
approach, Ed (M. F. PoWell, M. J. NeWman) Plenum Press, 
NeW York, NY 1995 p 495-524). The lipid A region of the 
LPS Was found to be responsible for the adjuvanticity. Lipid 
A, Which generally aids in Th1-type responses, enhances 
immune responses primarily through its ability to activate 
antigen-presenting cells (APC) and to induce the release of 
cytokines such as interferon-gamma (IFN-y) and IL-2. The 
strong toxicity of lipid A promoted the development of the 
detoxi?ed MPL, Which retains the adjuvant properties of lipid 
A but With much reduced side effects (A. J. Johnson, Adju 
vant action of bacterial endotoxins on the primary antibody 
response. In: M. Landy, W. Braun, (Eds.) Bacterial endotox 
ins. NeW BrunsWick: University Press, 1964 pp 252-262; J. R. 
Baldridge, R. T. Crane, Monophosphoryl lipidA (MPL) for 
mulations for the next generation of vaccines, Methods 1999 
19 103-107). Besides the immunostimulatory molecules such 
as the lipid A, particulates as vaccine adjuvants have been 
evaluated for many years (D. T. O’Hagan, M. Singh, R. K. 
Gupta, Adv. Drug. Del. Rev. 1998 32 225-246). Particulates, 
such as emulsions, microparticles, ISCOMs, liposomes, 
virosomes, and the virus-like particles (VLP), have compa 
rable dimensions to the pathogens the immune system 
evolved to combat. Therefore, it is reasonable to use particu 
lates as a vaccine delivery system. One of the most exten 
sively investigated is the poly (lactide-co-glycolide) (PLGA) 
microparticle. It has proven to be a potential vaccine adjuvant 
and/or delivery system for years (D. T. O’Hagan, J. Pharm. 
Pharmcol. 1998 59 1-10). Usually, vaccines Were incorpo 
rated into the microparticles for delivery (O’Hagan, 1998). 
HoWever, vaccines can also be adsorbed on the microparticles 
(J. Kreuter, P. P. Speiser, Infect. Immun. 1976, 13: 204-210). 
For example, KaZZaZ et al. (2000) recently demonstrated that 
PLGA microparticles With adsorbed HIV-1 p55 gag protein 
on their surface Were capable of inducing potent cell-medi 
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ated immune responses, including CTL, in mice folloWing 
intramuscular immunization (J. KaZZaZ, J. Neidleman, M. 
Singh, G. Ott, D. O’Hagan, J. Control. Rel. 2000 67 347-356). 
Surface adsorption of vaccines on microparticles has advan 
tage in that it avoids the damages to vaccines caused by the 
sonication and high-torque mechanical mixing often needed 
in the process of microparticle preparation. In addition, limi 
tation caused by the sloWness of vaccine release once being 
incorporated can also be avoided. Singh et al. (M. Singh, M. 
Briones, G. Ott, D. O’Hagan, Proc. Natl. Acad. Sci. 2000 97 
811-816) reported that the siZe of PLGA microparticles With 
adsorbed pDNA directly related to the strength of the result 
ing immune response; Wherein the relative ratio Was 300 
nm>1 micron>30 microns. The authors attributed this particle 
siZe relationship to the enhanced ability of the smaller par 
ticles to be taken up by antigen presenting cells. Nevertheless, 
particles less than 300 nm Were not investigated by the 
authors most likely since 300 nm particles that could be 
produced using the process described by the authors. 
As such, there is a need for a method to engineer nanopar 
ticles less than 300 nm and even less than 100 nm using a 
rapid and reproducible one-step process that may be con 
tained in one vessel Wherein said nanoparticles can be used to 
more e?iciently target protein antigen to antigen presenting 
cells. There is also a need for an effective adjuvant and/or 
delivery system for Tat to enhance both humoral and cellular 
Th1-type immune responses. 
SUMMARY OF THE INVENTION 
The foregoing and other needs are met by embodiments 
according to the present invention, Which provide a method of 
producing non-denatured, recombinant Tat protein that is free 
of bacterial RNA, the method comprising a step for removing 
bacterial RNA from the Tat protein and a method for purify 
ing, Without denaturing, Tat protein. 
The foregoing and other needs are met by embodiments 
according to the present invention, Which provide a non 
denatured, recombinant Tat protein that is free of bacterial 
RNA. 
The foregoing and other needs are further met by embodi 
ments according to the present invention, Which provide a 
method for inducing humoral and cellular responses that Will 
lead to the destruction of HIV-infected cells, the method 
comprising administering to a subject, including a human 
subject, a humoral and cellular response inducing amount of 
a recombinant Tat protein With or Without an adjuvant and/ or 
Tat-delivery system according to the present invention. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The present invention Will become more fully understood 
from the detailed description given beloW. The accompanying 
draWings are presented for the purposes of illustration only, 
and thus are not intended to limit the scope of the present 
invention. 
FIG. 1 shoWs Tat binding to RNA. Lane 1 shoWs molecular 
Weight markers. Lane 2 shoWs transfer RNA. Lane 3 shoWs 
Tat protein (10 ug). Lane 4 shoWs Tat protein treated With 
highly puri?ed RNase for 20 min at room temperature. 
FIG. 2 shoWs a bar diagram that depicts the speci?c anti 
body response of four groups of mice that had been immu 
niZed With recombinant Tat 1-72 (SEQ ID NO:1) alone (a), 
and in combination With Alum (b), HPC (c), and HPC and 
Alum (d), according to the protocol described in Example 1 
(a). 
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FIG. 3 shows a bar diagram that depicts the induction of Tat 
1-72 (SEQ ID NO: 1) speci?c T cell responses from mice that 
had been immunized With Tat 1-72 (SEQ ID NO:1). T cell 
proliferation Was determined in the absence or the presence of 
Tat 1-72 (SEQ ID NO: 1) at a concentration of1 ug/ml or 10 
ug/ml, according to the protocol described in Example 1 (b). 
FIG. 4 shoWs the result of an RNAse protection assay that 
Was performed according to the protocol outlined in Example 
1 (c). The protected RNA fragments correspond to the cytok 
ines that are expressed by Tat immune T cells in response to 1 
ug/ml Tat 1-72 (SEQ ID NO:1). 
FIG. 5 depicts the results of the How cytometry protocol 
outlined in Example 2. The numbers in the upper right quad 
rant represent the percent K11 -26, CD4-cells. ShoWn are the 
results from a single mouse for each group. TWo groups of 
mice Were tested, and the results of the second group of 
animals (not shoWn) are identical to the results shoWn in FIG. 
5. 
FIG. 6 shoWs the effect of the concentration of Tat on the 
particle siZe ( ) and Zeta potential ( ) of the resulting Tat 
adsorbed nanoparticles. Data reported Were meanzS. D. 
(n:3). 
FIG. 7 shoWs the stability of the Tat-adsorbed nanopar 
ticles in simulated biological media. The particle siZes Were 
measured prior to incubation (White bars) and after incuba 
tion (black bars). 
FIG. 8 shoWs Tat-speci?c serum IgG (A) and IgM (B) 
levels measured 28 days after the initial immunization of four 
groups of mice, (i) mice immuniZed With Tat adjuvanted With 
Alum (lighter shaded bars), (ii) mice immuniZed With Tat 
adsorbed nanoparticles (NPs) (black bars), (iii) mice immu 
nized With Tat adjuvanted to lipid A (darker shaded bars) and 
(iv) naive mice (White bars) Naive mice are indicated by the 
Data reported Were meaniS. D. (n:5). * indicates that the 
results from the immuniZed mice Were signi?cantly different 
from that from the naive mice, Whereas there Was no signi? 
cant difference among the three immuniZed groups. 
FIG. 9 shoWs release of cytokines from isolated spleno 
cytes recovered from mice immuniZed With either Tat adju 
vanted With Alum, Tat adsorbed on nanoparticles (NPs), or 
Tat adjuvanted With lipidA on day 0 and day 14. Data reported 
Were meaniS. D. (n:3). * indicates the INF-y releases from 
the NPs and lipid A groups Were different from that of the 
others. ** indicates the INF-y release from the Alum group 
Was greater than that from the naive. *** indicates that the 
IL-4 release from the NPs Was signi?cantly loWer than that 
from the Alum. 
FIG. 10 illustrates in vitro proliferation of isolated spleno 
cytes recovered from mice immuniZed With either Tat adju 
vanted With Alum, Tat adsorbed on nanoparticles (NPs), or 
Tat adjuvanted With lipidA on day 0 and day 14. Data reported 
Were meaniS. D. (n:3). * indicates that the result from the 
NPs group Was signi?cantly different from that of the others. 
DETAILED DESCRIPTION OF THE INVENTION 
In one aspect of the present invention there is a therapeutic 
agent for treating or preventing HIV infection. In some 
embodiments according to the present invention, a vaccine is 
provided that is capable of eliminating part or all HIV viral 
load from an infected host by targeting the immune system to 
HIV-infected cells. In some embodiments, the invention is 
directed to treating HIV-1 infection. 
In some embodiments of the invention, the therapeutic 
agent includes an immunostimulatory recombinant Tat pro 
tein that retains the ability of being intemaliZed by cells and 
acts as an effective immunogen for the development of Th1 
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and CTL responses. In some embodiments according to the 
present invention, the inventive Tat protein is administered to 
a patient in need of such treatment early in the course of 
infection, such as during the presymptomatic stage, alone or 
in combination With other subunit vaccines. In other embodi 
ments, the inventive Tat protein is administered after the 
patient has manifested symptoms of HIV infection. 
In another aspect of the present invention there is a method 
for treating HIV infection. The inventive method comprises 
administering a recombinant Tat protein that elicits humoral 
and cellular immune responses, While avoiding immune sup 
pression. The humoral response provides neutraliZing anti 
bodies speci?c for Tat, Which eliminates viral Tat protein that 
is released from HIV-infected cells. The cellular immune 
response induces the activation of Th1 and CTL cells, Which 
then target and eliminate cells harboring HIV. 
The present inventors have surprisingly discovered that 
recombinant Tat protein tightly binds bacterial RNA, Which 
masks Tat epitopes. FIG. 1 shoWs Tat binding to RNA in 
samples analyZed by agarose gel electrophoresis folloWed by 
staining With ethidium bromide. The absence of signal in lane 
4 suggests that the Tat protein binds to RNA Which has the 
molecular mass of transfer RNA (1200 bp). The present 
inventors have further discovered that Tat protein copuri?es 
With endotoxin, Which may mask Tat epitopes, and/or sup 
press immune function. In a preferred embodiment a recom 
binant Tat protein is prepared that does not have RNA tightly 
bound to it, and that is substantially free of endotoxin con 
tamination. 
The present inventors have surprisingly discovered that 
recombinant Tat protein tightly binds bacterial RNA, Which 
masks Tat epitopes. FIG. 1 shoWs Tat binding to RNA in 
samples analyZed by agarose gel electrophoresis folloWed by 
staining With ethidium bromide. The absence of signal in lane 
4 suggests that the Tat protein binds to RNA Which has the 
molecular mass of transfer RNA (1200 bp). The present 
inventors have further discovered that Tat protein copuri?es 
With endotoxin, Which may mask Tat epitopes, and/or sup 
press immune function. In a preferred embodiment a recom 
binant Tat protein is prepared that does not have RNA tightly 
bound to it, and that is substantially free of endotoxin con 
tamination. 
The present inventors have discovered that Wild-type Tat 
1-72 (SEQ ID NO: 1) is capable of inducing signi?cant and 
speci?c humoral and T cell mediated immune responses, and 
that Tat 1-72 is not immunosuppressive in vivo. The term 
“Wild-type” refers to an amino acid sequence encoded by a 
cDNA that is identical to that encoded by the endogenous 
gene. Tat refers to the protein product of the tat gene. In still 
another aspect of the present invention there is a recombinant 
Tat 1-72 (SEQ ID NO: 1) that faithfully reproduces both the 
primary and tertiary structure of naturally occurring, Wild 
type Tat 1-72 (SEQ ID NO: 1). 
While the speci?c embodiments set forth beloW are 
directed to HIV-1, the puri?cation and therapeutic method 
ologies set forth herein are equally applicable to HIV-2, 
oWing to the recogniZed homology betWeen the tWo viral 
strains. As used in the general discussion of the invention, 
“HIV” refers to HIV-1 or HIV-2, unless otherWise speci?ed. 
Preferably, some embodiments of the present invention 
provide methods for using a recombinant Tat protein for 
inducing humoral and cellular responses in an animal, pref 
erably a mammalian animal, and more preferably a human. 
More preferably, the Tat protein is autonomously intemaliZed 
by cells; that is, not integrated into the host genome. As 
mentioned above, the second exon of Tat in?uences the ter 
tiary con?guration of Tat and greatly potentiates Tat cellular 
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uptake. Three forms of recombinant Tat proteins Were evalu 
ated for their immunogenic effects: Tat 1-86 (SEQ ID NO: 2), 
Tat 1-72 (SEQ ID NO: 1), and mutated Tat 1-86 (mTat1-86) 
(SEQ ID NO: 3). Tat 1-72 (SEQ ID NO: 1) protein Was 
derived from the HIV-1 BRU exon 1; and Tat 1-86 (SEQ ID 
NO: 2) Was derived from HIV-1 BRU exons 1 and 2. The 
HIV-1 BRU exons Were obtained from Dr. Richard Gaynor 
through the AIDS repository at the NIH. Mutated Tat 1-86 
(mTat 1-86) (SEQ ID NO: 3), Which is derived from exon 1, 
Was modi?ed to contain a single amino acid substitution at 
position 22, Whereby Cys 22 Was substituted by a Gly using 
site directed mutagenisis (Rossi, C. et al. 1997 Gene Ther. 
411261; Caselli, B. et al. 1999 J. Immunol. 16215631). The 
protein mTat 1-86 is a transdominant Tat mutant that lacks 
HIV-1 transactivation activity, and has been shoWn to elicit 
immune response against Wild-type Tat protein in a mouse 
model. 
The method for preparing recombinant proteins has been 
described previously by the inventors (Ma, M. and Nath, A. 
1997 J.V“1rol. 7112495; Nath,A. etal. 1996 J. Virol. 7011475; 
Nath, A. et al. 1996 J. Neurovirol. 2:17; Holden, C. P. et al. 
1999 Neuroscience 9111369; Haughey, N. J. et al. 1998 J. 
Neurovirol. 41353; Nath, A. et al. 2000 Ann. Neurol. 47; 
Haughey, N. J. et al. 1999 J. Neurochem. 7311363). Brie?y, 
Wild-type Tat 1-72 (SEQ ID NO: 1) and Tat 1-86 (SEQ ID 
NO: 2), and mTat 1-86 (SEQ ID NO: 3) Were subcloned into 
a bacterial vector PinPoint Xa-2 (Promega) to express Tat as 
fusion proteins that are naturally biotinylated at the N-terrni 
nus. E. Coli bacteria Were transformed With the resulting 
vector, and Were groWn in 200 ml of Luria Broth for 18 hours 
and in 2 L of Terri?c Broth for 1 hour. The cells Were har 
vested, and lysed, and the biotinylated Tat protein Was puri 
?ed by a?inity chromatography using a soft release avidin 
resin. Tat Was cleaved from the fusion protein by enzymatic 
cleavage using factor Xa, eluted and desalted using a PD 10 
column. It is obvious to those skilled in the art that the 
genomic and amino acid sequence and length of Tat varies 
amongst different strains of HIV. Also, the protein could be 
produced in various strains of E. coli, other organisms or 
cells. 
As mentioned above, the inventors have surprisingly dis 
covered that bacterial RNA remains tightly associated With 
the Tat proteins throughout the puri?cation process. In order 
to avoid masking of Tat epitopes by bound bacterial RNA, the 
recombinant Tat-bound RNA is removed by digestion With 
RNAse. Endotoxin Was removed by adsorption onto poly 
mixin B. The puri?ed Tat Was then stored as a 5% glycerol 
stock at —800 C. The protein preparation Was analyzed by 
Western blot and a LTR activation assay for purity, and for the 
presence of endotoxin. Typically, the method described yields 
0.5 mg of protein per liter of bacterial culture. The protein is 
>98% pure, and contains less than 1 pg of endotoxin per gram 
of Tat protein. The puri?ed Tat proteins Were used in all 
processes of the present invention as described beloW. 
In yet another aspect of the invention there is provided a 
therapeutic composition for treating HIV infection, said com 
position comprising an effective amount of an immunostimu 
latory recombinant Tat protein and an adj uvant. Suitable com 
positions according to the present invention comprise a 
physiologically acceptable or pharmacologically acceptable 
composition, suitable for use in a method of treating early 
HIV infection. Administering said protein evokes cellular and 
humoral responses that lead to the elimination of HIV-in 
fected cells at early stages of infection, such as during the 
asymptomatic phase. While not Wishing to be bound by 
theory, it is believed that this mode of action occurs by stimu 
lating production of CTL, by stimulation of lytic cytokines by 
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Th1 cells, by evoking antibody dependant cellular cytotoxic 
ity or by complement-dependent cell lysis. In a preferred 
embodiment, the immunization protocol induces a Th1 and 
CTL response to effectively eliminate HIV infected cells that 
express viral Tat in vivo. In any case, administering the inven 
tive recombinant Tat protein as an antigen to an animal or a 
patient infected With HIV, eliminates cells harboring the HIV 
and restores immune responses lost as a result of the infec 
tion. The method of administering may be oral, topical, nasal 
or parenteral. Parenteral administration may include intrave 
nous, intramuscular, subcutaneous, intraderrnal or intraperi 
toneal. Most preferably, the therapeutic agent should be for 
mulated so as to be suitable forparenteral administration to an 
animal, and to be suitable for treating humans. 
Previously developed vaccines have combined the Tat anti 
gen With either RIBI or Alum adjuvants, (Cafaro, A. et al. 
1999 Nat. Med. 51643), Tat-ovalbumin conjugates (Moy, P. et 
al. 1996 Mol. Biotechnol. 61105), or Tat-encapsulated cat 
ionic liposomes (Huang, L. et al. 1995, Biochem. Biophys. 
Res. Commun. 2171761). Other vaccines have used plasmid 
DNA to express Tat protein in vivo. (Caselli, E. et al. 1999 J. 
Immunol. 16215631). HoWever, the CTL responses to these 
immunization strategies have been inadequate or remain 
uncharacterized. Alternatively, previous immunization proto 
cols using particulate forms of antigen have induced strong T 
cell proliferative responses. The previously devised particu 
late delivery systems include polylactic acid-co-glycolic acid 
(PLGA) microspheres (Cleland, J. L. et al. 1998 J. Pharm. 
Sci. 8711489; Partidos, C. D. etal. 1997 J. Immunol. Methods 
206114345-47; Israel, Z. R. et al. 1999 AIDS Res. Hum. 
Retroviruses 1511121), liposomes (Eckstein, M. et al. 1997 
Vaccine 151220; Lutsiak, C. M. et al. 1998 J. Pharm. Sci. 
8711428; Zheng, L. et al. 1999 AIDS Res. Hum. Retroviruses 
1511011; Zhou, F. et al., 1992 J. Immunol., 14911599), and 
alginate microspheres (BoWersock, T. L. et al., 1999, Vaccine 
1711803; BoWersock, T. L. etal., 1998, Immunol. Lett. 60137; 
Cho, N. H. et al., 1998, J. Controlled Release 531215). HoW 
ever, the disadvantages of the previously used particulate 
systems include that that they are dif?cult and expensive for 
large-scale production. Because the peptide antigen is encap 
sulated in the particulate delivery system during the manu 
facturing process, the stability of the peptide must Withstand 
high-torque mechanical forces during the mixing step(s). 
Control of optimal particle size, encapsulation ef?ciency and 
separation of unencapsulated protein from the particulate 
carrier are also problematic. 
The present inventors have devised a particulate system 
that includes hydroxypropyl cellulose (HPC), Which forms 
gel-particles containing Tat spontaneously at 35-370 C., and 
avoids potentially damaging high-torque mechanical mixing 
needed to entrap the antigen. 
The present inventors have shoWn that administering an 
immuno stimulatory recombinant Tat protein With an adjuvant 
to an animal induces signi?cant and speci?c humoral and T 
cell responses. The present inventors assessed T cell and 
antibody responses in groups of mice that had been immu 
nized subcutaneously With Tat 1-72 alone or in combination 
With one of the adj uvants1 Alum (aluminum hydroxide), HPC, 
or ALUM+HPC. As shoWn in FIG. 2, signi?cant antibody 
responses Were attained, in all four groups With the greatest 
responses seen in the Tat+Alum and Tat+HPC+Alum groups. 
The latter groups achieved a total anti-Tat antibody titre of 
about 1 12000. Isotype speci?c ELISA revealed a predominant 
IgG1 antibody response, and no detectable IgG2 antibodies. 
This result indicates that Tat 1-72 elicits a substantial humoral 
response. The inventors envision that several types of particu 
late material including but not limited to the following: lipo 
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somes, nanoparticles and microspheres may be used to gen 
erate an immune response to Tat. 
The auxiliary and inguinal lymph node cells of the mice 
immunized With Tat 1-72, Were isolated and cultured for 5 
days in the presence or absence of Tat 1-72, and T cell pro 
liferation Was determined by 3H-Tdr during the last 18 hours 
of the 5-day incubation. The inventors discovered that Tat 
1-72 immunization induces Tat-speci?c T cell proliferation 
from the draining lymph nodes. (FIG. 3). The naive T cells 
from the control group proliferated signi?cantly in response 
to 15 ug/ml (1 uM) Tat 1-72, Which indicates that Tat 1-72 is 
mitogenic at this concentration. In contrast T cells from Tat 
1-72-immuniZed mice shoWed even greater proliferation in 
the presence of 1 ug/ml concentration of Tat 1-72, indicating 
that the proliferative T cell response is speci?c to the Tat 
antigen. Therefore, recombinant Tat 1-72 is capable of induc 
ing signi?cant and speci?c humoral and T cell mediated 
responses. 
The immune system of the mouse is very similar to the 
human immune system, and the person having skilled in the 
art Will recogniZe that successful induction of anti-Tat 
immune response in the mouse model is strongly predictive of 
a similarly effective immune response in humans. 
To determine the cytokine pro?le of the Tat-speci?c T cells, 
cytokine mRNA levels Were quantitated by multiprobe ribo 
nuclease protection assay (Pharmingen) (FIG. 4). The cytok 
ines expressed Were predominantly IL-4, IL-9, IL-13 With 
relatively loW levels of INF-y, indicating a Th2 response. The 
production of IgG1 and Th2 T cell response are consistent 
With the knoWn Th2 inducing property of Alum (Brewer, J. M. 
et al. 1999 J. Immunol. 163:6448). 
Another embodiment of the present invention provides for 
a recombinant Tat protein that is not immunosuppressive. 
Several studies cited above have shoWn that Tat is immuno 
suppressive. HoWever, the present inventors have discovered 
that neither Tat 1-72 nor Tat 1-86 produced by the foregoing 
process (i.e. RNAse digestion and polymixin column treat 
ment) shoW any immunosuppressive effects. This result is 
surprising and unexpected. While not Wishing to be bound by 
theory, it is believed that this result can be at least in part 
explained by differences betWeen the previously developed 
experimental protocols and the protocol according to the 
present invention, and in particular the absence from the 
inventive TAT 1-72 and Tat 1-86 of bacterial RNA and cyto 
toxin, as Well as the retention of the folding structure of the 
recombinant proteins. 
The previous studies on the apoptotic effect of Tat Were 
carried out in vitro, While the present inventors evaluated 
Tat-induced immunosuppression in vivo using the in vivo 
DO11.10 TCR transgenic T cell adoptive transfer system. In 
this system, T cells from mice that are sensitiZed to OVA are 
transferred to a normal BALB/c mouse, and clonal expansion 
of antigen speci?c T cells in response to OVA or OVA that is 
coinjected With a form of Tat, can be measured by How 
cytometry using clonotypic monoclonal antibody KJ1-26 
(Pape, K. et al. 1997 Immunol. Revl. 56:67). FolloWing adop 
tive transfer of OVA speci?c D01 1.10 TCR transgenic cells 
into normal BALB/ c mice, clonal expansion Was observed by 
How cytometry of lymph node (LN) or spleen cells in 
response to OVA immuniZation. This response is dependent 
on OVA presentation in a class II restricted manner on APCs 
and requires B7-CD28 interaction (Kearney, E. R. et al. 1995 
J. Immunol. 155:1032). Because Tat 1-86 Was shoWn to sup 
press the response to a coinjected antigen in another system 
(Cohen, S. S. et al. 1999 Proc. Natl. Acad. Sci. USA 
96110842), the inventors expected that Tat 1-86 Would also 
suppress the response to OVA in their system. Surprisingly, 
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When Tat 1-72 or Tat 1-86 Were tested, neither protein caused 
immunosuppression of systemic clonal expansion displayed 
any immunosuppressive activity. A representative result is 
shoWn in Example 2 and the accompanying FIG. 5. 
The present inventors have also devised a nanoparticle 
delivery system for delivering recombinant Tat protein. In 
still another embodiment, the present invention provides Tat 
adsorbed nanoparticles. Tat-adsorbed nanoparticles are used 
to improve both antibody production and cell-mediated 
immune responses. It has also been shoWn that administering 
an immuno stimulatory recombinant Tat protein With a nano 
particle-based vaccine delivery system to an animal induces 
enhanced humoral and Thl-type cellular immune response. 
The present inventors assessed antibody and T-cell responses 
in groups of mice that had been immuniZed subcutaneously 
With Tat 1-72 adjuvanted With Alum or lipid A, and Tat 
adsorbed nanoparticles. 
First, anionic nanoparticles Were prepared as previously 
described in Cui, Z. and Mumper, R. J ., Coating of CationiZed 
Protein On Engineered Nanoparticles Results In Enhanced 
Immune Responses. Int J Pharrn. 2002 238 (1 -2):229-39, 
incorporated herein by reference in its entirety. Brie?y, emul 
sifying Wax (2 mg) Was accurately Weighed into 7-ml glass 
scintillation vials and melted on a hot plate at 50-550 C. Seven 
hundred (700) ML of de-ioniZed and ?ltered (0.22 pm) Water 
Were added to the melted Wax While stirring to form homog 
enous milky slurry. Then, 300 ML of SDS stock solution (50 
mM) Were added While stirring to obtain a ?nal SDS concen 
tration of 15 mM. Within seconds, clear O/W microemulsions 
formed. These microemulsions Were then simply cooled 
(cured) to room temperature While stirring to form nanopar 
ticles. For particle siZing, the nanoparticle suspension Was 
diluted With de-ioniZed and ?ltered (0.22 pm) Water and the 
particle siZe Was measured at 900 light scattering for 90 s at 
250 C. The Zeta potential of engineered nanoparticles Was 
also measured using a Zeta SiZer 2000 from Malvern Instru 
ments, Inc. (Southborough, Mass.). 
The nanoparticles Were puri?ed using gel permeation chro 
matography (GPC) With a Sephadex G-75 column. Varying 
amounts of Tat in Water Were then added into the puri?ed 
nanoparticle suspension folloWed by gently pipetting and 
slightly vortexing. The mixtures Were then alloWed to stay on 
laboratory bench for at least 30 min forbinding before further 
use. 
Then, the present inventors prepared Tat-adsorbed nano 
particles.As used herein, “Tat-adsorbed nanoparticles” refers 
to the adhesion of Tat protein to the surface of nanoparticles. 
HIV-1 Tat is a small protein encoded by tWo exons. The basic 
domain (aa 49-72) is rich in basic amino acids, Which ren 
dered the protein to be overall positively charged (K. A. Jones, 
B. M. Peterlin, Ann. Rev. Biochem. 1994 63 717). Therefore, 
Tat Was able to bind on the surface of the anionic nanopar 
ticles via strong electrostatic interactions.As shoWn in FIG. 6, 
the particle siZe and the Zeta potential of the nanoparticles 
prior to protein binding Were 105111 nm and —65.1:2 mV, 
respectively. With more Tat being adsorbed on the surface of 
the nanoparticles, the siZe of the resulted nanoparticles 
increased, and the Zeta potential of the nanoparticles became 
less negative. At a ?nal Tat concentration of 25 ug/mL, the 
adsorption ef?ciency of Tat to the anionic nanoparticles Was 
approximately 100% as con?rmed by both gel permeation 
chromatography and ultra?ltration (MW cut-off, 50 kDa). 
This can be attributed to the fact that excess of anionic nano 
particles Were used for adsorption. The Tat-adsorbed nano 
particles Were stable in several simulated biological media as 
shoWn in FIG. 7. It Was estimated that there Were approxi 
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mately 6-7 Tat molecules being adsorbed on each nanopar 
ticle (?nal Tat concentration, 25 pg/mL). 
Further, the present inventors have shoWn that Tat adsorbed 
nanoparticles result in enhanced humoral and Th-1 type 
immune response. Both humoral and Th-l type cellular 
immune responses Were assessed in groups of mice that had 
have been immuniZed subcutaneously With Tat 1-72 adju 
vanted With Alum, Tat 1-72 adjuvanted With lipid A, and 
Tat-adsorbed nanoparticles. Ten to tWelve Week old female 
mice (Balb/C) from Harlan Sprague-DaWley Laboratories 
Were used for all animal studies. 
Three groups of mice Were immuniZed With doses of either 
(i) Tat (5 pg)-coated nanoparticles (15-20 pg), (ii) 5 pg of Tat 
adjuvanted With 15 pg of Alum as a control for Th2 immune 
responses, or (iii) 5 pg of Tat adjuvanted With 50 pg of lipidA 
as a control for Th1 immune responses. In addition, 5 naive 
mice Were untreated and used as negative control. TWo hun 
dred (200) pl of each formulation in 10% lactose Was injected 
on one site on the back. Prior to immuniZation, mice Were 
anesthetiZed using pentobarbital (i.p.). On day 28, the mice 
Were anesthetiZed and bled by cardiac puncture. Sera Were 
separated and stored at —20° C. for assessment of antibody 
and T cell proliferative responses. 
After immunization and according to previously described 
methods (Cui and Mumper, Int. J. Pharm. 2002 238 (1-2): 
229-39), the present inventors compared using ELISA Tat 
speci?c antibodies (IgG and IgM) in serum of Tat-adsorbed 
nanoparticles to Tat adjuvanted With Alum or lipidA. Brie?y, 
Costar high binding 96-Well assay plates Were coated With 50 
pL of Tat protein (8 pg /mL) overnight at 4° C. The plates Were 
then blocked for 1 hr at 37° C. With 4% bovine serum albumin 
(BSA)/4% NGS (Sigma) solution (100 pL/Well) made in 
1><PBS/TWeen 20 (Scytek). Mouse serum (50 pL/Well, 
diluted for appropriate folds in 4% BSA/4% NGS/PBS/ 
TWeen 20) Was incubated for 2 hr at 37° C. After Washing 
three times With PBS/Tween 20 buffer, anti-mouse IgG HRP 
F(ab')2 fragment from sheep or Goat Anti-Mouse IgM-HRP 
(Southern Biotechnology Associates, Inc., Birmingham, 
Ala.) (diluted 1:3,000 in 1% BSA) Was added (50 p/Well) and 
incubated for 1 hr at 37° C. Plates Were Washed three times 
With PBS/Tween 20 buffer. Finally, the samples Were devel 
oped With 100 pL TMB substrate for 30 min at room tem 
perature and then stopped With 50 pL of 0.2 M H2SO4. The 
optical density (OD) of each Well Was measured using a 
Universal Microplate Reader (Bio-Tek Instruments, Inc., 
Winooski, Vt.) at 450 nm. 
As shoWn in FIGS. 8A and 8B, the antibody titers-from 
mice immuniZed With Tat-adsorbed nanoparticles, and Tat 
adjuvanted With Alum or lipid A Were strong. The data 
shoWed Tat-adsorbed nanoparticles Was comparable to that 
from the mice immuniZed With Tat adjuvanted With Alum. 
To determine the cytokine release and the proliferation of 
isolated splenocytes of Tat-adsorbed nanoparticles in com 
parison to Tat adj uvanted With Alum and Tat adjuvanted With 
lipid A, splenocyte preparation Was completed as previously 
described above (Cui and Mumper, Int J. Pharm. 2002 238 
(1-2)229-39). Brie?y, spleens from each group of mice Were 
pooled together and placed into 5 mL of HBSS (Hank’s 
Balanced Salt Solution) (1><) in a Stomacher Bag 400 from 
Fisher Scienti?c (Pittsburgh, Pa.). The spleens Were homog 
eniZed at high speed for 60 s using a Stomacker HomogeniZer. 
Cell suspensions Were then transferred into 15 mL Falcon 
tube and ?lled to 15 mL With 1><ACK buffer (156 mM of 
NH4Cl, 10 mM of KHCO3, and 100 pM of EDTA) for red 
blood cell lysis. After 5-8 min at room temperature, the sus 
pension Was spun doWn at 1,500 rpm for 7 min at 4° C. After 
pouring off the supernatant, the cell pellet Was re-suspended 
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in 15 mL HBSS. The suspension Was then spun doWn at 1,500 
rpm for 7 min at 4° C. After Washed once With 15 mL of 
RPMI-1640 (BioWhittaker, Walkersville, Md.) supple 
mented With 10% fetal bovine serum (FBS) (Sigma, St. 
Louis, Mo.) and 0.05 mg/mL of gentamycin (Gibco BRL), 
the cells Were re-suspended in RPMI 1640 media (5 mL). 
For cytokine release, isolated splenocytes (1><106 cells/ 
Well) With three replicates (n:3) Were seeded into a 48-Well 
plate. (Costar), and stimulated With 2 pg/Well of Tat protein. 
After incubation at 37° C. With 5% CO2 for 48 hours, the 
splenocytes Were spun doWn and the supernatant Was col 
lected and stored at —20° C. prior to further use. Cytokine 
concentration (IFN-y and IL4) in the supematants Was deter 
mined using ELISA kits from Pierce-Endogen (Rockford, 
111.). 
For splenocyte proliferation, isolated splenocytes (1><106 
cells/Well) With three replicates (n:3) Were seeded into a 
48-Well plate (Costar), and stimulated With 0 or 2 pg/Well of 
Tat protein. After incubation at 37° C. With 5% CO2 for 96 
hours, 60 pL of the combined MTS/PMS solution (Promega) 
Was pipetted into each Well (20 pL/100 pL of cells in 
medium). After an additional 4.5 hours of incubation at 37° C. 
With 5% CO2, the absorbance at 490 nm Was measured using 
a Universal Microplate Reader. The cell proliferation Was 
reported as the % increase of the OD490 of the stimulated cells 
(2 pg/Well) over the OD490 of un-stimulated cells (0 pg/Well) 
(i.e., 100><(OD490StimuZatefOD490un_s?mulated)/ 
OD490un-st'imulated ' 
A representative result for Tat-adsorbed nanoparticle 
cytokine release and cell proliferation are shoWn in Example 
4 and the accompanying FIGS. 9 and 10. 
Another embodiment of the present invention provides a 
method for inhibiting HIV infection in an animal. Said 
method comprises administering a pharmacologically active 
amount of immuno stimulatory recombinant Tat protein to an 
animal, preferably in a mammalian animal, and more prefer 
ably in a human. 
In another aspect of the present invention, Tat-adsorbed 
nanoparticles provides a delivery system for, and a method for 
delivering, other protein antigens. The Tat-adsorbed nanopar 
ticles delivery system is used in the treatment and prevention 
of cancer and infectious disease. 
The present invention may be more fully appreciated upon 
consideration of the folloWing, non-limiting, examples. 
EXAMPLES 
Example 1 
Tat 1-72 Induces Humoral and Cell Mediated 
Responses 
The present example is provided to demonstrate the effec 
tiveness of Tat 1-72 as an immunogen. 
(a) To determine the immunogenicity of Tat 1-72, 4 groups 
each of 5 mice Were immuniZed With 10 pg of puri?ed Tat 
alone, Tat+Alum, Tat+HPC, or Tat+HPC+Alum. The mice 
Were immuniZed subcutaneously at one-Week intervals for 
three Weeks. At the end of the fourth Week, serum Was col 
lected from each animal, and antibody and T cell proliferative 
responses Were assessed. Tat speci?c antibodies Were 
detected by sandWich ELISA on Tat coated ELISA plates, and 
using rabbit-anti-mouse Ig secondary antibody. The results 
are shoWn in FIGS. 2(A)-(D). 
Signi?cant Tat-speci?c antibody responses Were obtained 
in all four groups. The strongest response Was induced in the 
tWo animal groups Which had been immuniZed With Tat in 
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combination WithAlum or HPC+Alum. The antibody titre for 
both groups Was 1:2000. Isotype-speci?c ELISA revealed a 
predominant IgGl response, and no detectable IgG2 antibod 
ies. 
(b) To determine the ability of Tat 1-72 to induce Tat 
speci?c T cell proliferation. Four groups each of 5 mice Were 
immunized as described above. A ?fth group of mice Was 
used as a control group, Which Was not immunized With Tat 
1-72. The axilliary and inguinal lymph node cells Were iso 
lated, and cultured for 5 days in the presence or absence of 
either 1 ug/ml or 15 pg/ml Tat 1-72. Proliferation of the T cells 
Was determined as a function of incorporation of 3H-Tdr 
during the last 18 hours of incubation. 
The results are shoWn in FIG. 3. Tat 1-72 induced prolif 
eration of naive T cells from the control group at the Tat 1-72 
concentration of 15 pg/ml. I pg/ml Tat 1-72 did not have a 
signi?cant effect on the proliferation of the naive T cells. 
However, Tat 1-72 induced signi?cant increase in the prolif 
eration of the T cells from the Tat-immunized animals. The 
signi?cant changes Were seen When either concentration of 1 
pg/ml or 15 pg/ml Tat 1-72 Was used. This result indicates that 
the proliferative response Was Tat 1-72-speci?c. 
(c) To determine the cytokine pro?le of the proliferating T 
cells, cytokine mRNA levels Were quantitated as folloWs. 
Tat-immune T cells in culture Were incubated With 1 pg/ml 
Tat 1-72 for three days. Total T cell RNA Was isolated by 
guanidinium isothiocynate, and extracted using phenol. The 
RNA Was hybridized to 32P-labelled RNA probes using the 
Pharmingen MCK-l multiprobe cytokine ribonuclease pro 
tection kit. After hybridization, unprotected RNA Was 
digested using RNAse, and the protected fragments Were 
resolved on a 8% polyacrylamide/urea sequencing gel. The 
gel Was dried, and the RNA bands Were visualized and quan 
titated using a Storm 860 phosphor imager. 
The results of the assay are shoWn in FIG. 4, and shoW that 
the cytokines that Were predominantly expresses Were IL-4, 
IL-9 and IL-13. Relatively loW levels of INF-y Were also 
observed. 
Example 2 
Tat 1-72 does not Induce Immunosuppression In 
Vivo 
The present example is provided to shoW the utility of Tat 
1-72 as an immunogen, Which does not induce immunosup 
pression. 
The applicants used the in vivo D01 1. 10 TCR transgenic 
T cell adoptive transfer system to evaluate the effect of Tat 
1-72 on the ability of D01 0. 11 T cells to undergo clonal 
expansion in vivo. OVA-speci?c DO 10.11 TCR transgenic T 
cells Were transferred to normal BALB/c mice, and clonal 
expansion of the T cells Was evaluated folloWing administra 
tion ofOVA in the presence or absence ofTat 1-72. D01 0.11 
T cells, equivalent to 2.5><10 6 KJI 26, CD4+ cells, Were 
transferred by intravenous administration into unirradiated 
BALB/c mice. Three days later, three groups of mice Were 
given 200 pg OVA peptide 323-339, OVA 323-339 in combi 
nation With 10 pg Tat 1-72, or OVA 323-339 in combination 
With 10 pg Tat 1-86. The injections Were repeated on tWo 
consecutive days. Axillary and inguinal lymph node cells 
Were isolated on the third day. The cells Were stained With 
KJI-26-FITC and anti-CD4-PE, and quantitated by How 
cytometry. 
The results are shoWn in FIG. 5. The numbers in the upper 
right hand quadrants represent the percentage of KJ1-26, 
CD4+ cells. Immunization With the OVA peptide alone 
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induced in vivo clonal expansion of T cells. This result is 
represented by the 3.46% KJ-positive cells in the OVA mice 
(FIG. 5B) versus the 0.57% in the control group (FIG. 5A). 
The percentage KJ1-26 positive cells in the Tat 1-72 (FIG. 
5C) and in the Tat 1-86 (FIG. 5D) Were not signi?cantly 
different from the cells of group B. This result indicates that 
neither Tat 1-72 nor Tat 1-86 did not suppress T cell prolif 
eration in vivo. 
Example 3 
Preparation of Tat-Adsorbed Nanoparticles 
The present example is provided to describe the prepara 
tion of Tat-adsorbed nanoparticles. 
Nanoparticles Were prepared as described above, having a 
particle size and zeta potential prior to protein binding of 
105111 nm and —65.1:2 mV, respectively, as shoWn on FIG. 
6. Tat protein Was adsorbed on the surface of the GPC puri?ed 
anionic nanoparticles by gently mixing 25 pg/mL of Tat With 
1 mL of GPC puri?ed nanoparticles in 10% lactose. The 
Tat-adsorbed nanoparticles Were then co-incubated With 
either phosphate-buffered saline (PBS, 10 mM, pH7.4), fetal 
bovine serum (10%, v/v) in normal saline, or 10% (W/v) 
lactose for 30 min at 370 C. The particle size stability Was 
veri?ed in several simulated biological media prior to incu 
bation (White bars) and after incubation (black bars) as shoWn 
on FIG. 7. 
Example 4 
Tat-Adsorbed Nanoparticles Induces Enhanced 
Humoral and Cell Mediated Responses 
The present example is provided to demonstrate the effec 
tiveness of Tat-adsorbed nanoparticles. 
(a) To determine the immunogenicity of Tat-adsorbed 
nanoparticles, mice Were tWice immunized With either Tat (5 
pg) adjuvanted With Alum (15 pg, GlaxoSmithKline), Tat (5 
pg) adsorbed on nanoparticles, or Tat (5 pg) adjuvanted With 
lipidA (50 pg) on day 0 and day 14. On day 28, the mice Were 
sacri?ced. Mice Were harvested on day 28. A fourth group of 
naive mice Were untreated and used as negative control. The 
sera Were diluted as indicated prior to ELISA. 
ShoWn in FIG. 8 are the Tat-speci?c antibody levels for IgG 
(FIG. 8A) and IgM. (FIG. 8B) in serum. The antibody 
responses Were strong since even after 10,000-fold of dilu 
tion, the IgG titers from the immunized mice Were still 2.3 
3 .0-fold greater than that from the naive mice. Moreover, the 
antibody titers from mice immunized With the Tat-adsorbed 
nanoparticles Were comparable to that from the mice immu 
nized With Tat adjuvanted With Alum, a “gold” standard adju 
vant for antibody induction. Statistical analyses (ANOVA) 
did not reveal any signi?cant difference in both IgG and IgM 
among the three groups of immunized mice. 
(b) To determine the cytokine pro?le of the proliferating T 
cells, mice Were tWice immunized With either Tat (5 pg) 
adjuvanted With Alum (15 pg, GlaxoSmithKline), Tat (5 pg) 
adsorbed on nanoparticles, or Tat (5 pg) adjuvanted With lipid 
A (50 pg) on day 0 and day 14. On day 28, the spleens Were 
removed and splenocytes Were prepared as described above. 
The isolated splenocytes, (1 ><106 cells/Well) With three repli 
cates (n:3) Were seeded into a 48-Well plate (Costar), and 
stimulated With 2 pg/Well of Tat protein. After incubation With 
Tat (2 pg/5><106 cells) at 370 C. With 5% CO2 for 48 hours, the 
splenocytes Were spun doWn and the supernatant Was col 
lected and stored at —200 C. prior to further use. Naive mice 
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Were untreated and used as negative control. Cytokine con 
centration (lFN-y and 1L-4) in the supernatants Was deter 
mined using ELISA kits from Pierce-Endogen (Rockford, 
Ill). 
The results are shoWn in FIGS. 9 and 10. Strong and sig 
ni?cant differences Were observed for the in vitro cytokine 
release and proliferation of the isolated splenocytes among 
these three groups. The overall level of 1L-4 release Was loW 
for all groups. More importantly, Alum as adjuvant led to the 
18 
(l ><l06 cells/Well) With three replicates (n:3) Were seeded 
into a 48-Well plate (Costar), and stimulated With Tat (0 or 2 
pg/5><l06 cells). After incubation With Tat at 37° C. With 5% 
CO2 for 96 hours, 60 pL of the combined MTS/PMS solution 
(Promega) Was pipetted into each Well (20 pL/l 00 pL of cells 
in medium). After an additional 4. 5 hours of incubation at 37° 
C. With 5% CO2, the absorbance at 490 nm Was measured 
using a Universal Microplate Reader. The cell proliferation 
Was reported as the % increase of the OD 490 of the stimulated 
highest 1L-4 release (FIG. 9B) and very Weak lFN-y release 10 cells (2 pg/Well) over the OD490 of un-stimulated cells (0 
(FIG. 9A). Also, lipid A as adjuvant led to the highest lFN-y pg/Well) (i.e., l00><(OD490S?muZatefOD490Mn_mmmated)/ 
release, an indication of Th1 immune responses (FIG. 9A). OD490W_Sn-mmated). Naive mice Were untreated and used as 
The nanoparticles adsorbed With Tat resulted in lFN-y level negative control. 
similar to that from the lipid A adjuvanted Tat and 33-fold As shoWn in FIG. 10. Tat-adsorbed nanoparticles also 
higher than that from the Alum adjuvanted Tat. This observa- 15 resulted in greater proliferation of isolated splenocytes than 
tion, combined With the fact that the 1L-4 release from sple- Tat adjuvanted WithAlum, an indication of enhanced memory 
nocytes isolated from mice immuniZed With the nanoparticles immune response from the nanoparticles. There Was no dif 
adsorbed With Tat Was signi?cantly loWer than that from mice ference betWeen the Naive and the Alum groups. 
immuniZed With Alum adjuvanted Tat, strongly suggested The foregoing illustrative examples are provided to dem 
that the Tat-adsorbed nanoparticles led to Thl biased immune 20 onstrate the principles of the invention, and are not intended 
responses. to be limiting. One of skill in the art Will recogniZe that 
(c) To determine the ability of Tat-adsorbed nanoparticles additional embodiments are possible Within the scope of the 
to induce Tat-speci?c T-cell proliferation, mice Were tWice present invention, and the presentation of the foregoing 
immuniZed With either Tat (5 pg) adjuvanted With Alum (l 5 examples is not meant to imply limitation of the invention to 
pg, GlaxoSmithKline), Tat (5 pg) adsorbed on nanoparticles, 25 the examples. 
or Tat (5 pg) adjuvanted With lipidA (50 pg) on day 0 and day All references cited herein, including patents, patent appli 
14 On day 28, the spleens Were removed and splenocytes cations and non-patent literature references, are expressly 
Were prepared as described above. The isolated splenocytes incorporated herein by reference. 
SEQUENCE LISTING 
<l60> NUMBER OF SEQ ID NOS: 3 
<211> LENGTH: 72 
<212> TYPE: PRT 
<213> ORGANISM: HIV 
<4oo> SEQUENCE: 1 
Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser 
1 5 1 o 1 5 
Gln Pro Lys Thr Ala Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Phe 
2 o 2 5 3 0 
His Cys Gln Val Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly 
3 5 4 o 4 5 
Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala His Gln Asn Ser Gln Thr 
5 o 5 5 6 0 
His Gln Ala Ser Leu Ser Lys Gln 
6 5 7 o 
<211> LENGTH: 86 
<212> TYPE: PRT 
<213> ORGANISM: HIV 
<4oo> SEQUENCE: 2 
Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser 
1 5 1 o 1 5 
Gln Pro Lys Thr Ala Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Phe 
2 o 2 5 3 0 
His Cys Gln Val Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly 
3 5 4 o 4 5 


